GlassScriptPhysician profile
Damien Eugene Earl
NPI 1265774566
$7,728.84
in general payments reported to CMS, 2019-2025
47 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,022 · 2020: $1,059 · 2021: $1,219 · 2022: $1,265 · 2023: $855 · 2024: $1,117 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.44 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,130.18 | 2020-2025 | Ubrelvy, Botox, Qulipta |
| Genzyme Corporation | $543.02 | 2019-2025 | |
| Ucb, INC. | $421.92 | 2020-2025 | Briviact, Rystiggo |
| Sk Life Science, INC. | $421.31 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $407.63 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $404.55 | 2019-2024 | Ultomiris |
| Acadia Pharmaceuticals INC | $347.41 | 2019-2025 | Nuplazid |
| Horizon Therapeutics Plc | $247.14 | 2021-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $219.88 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $208.34 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $197.39 | 2020-2021 | |
| Genentech USA, INC. | $152.62 | 2021-2024 | Enspryng, Ocrevus Zunovo, Ocrevus |
| Amgen INC. | $139.38 | 2019-2021 | |
| Livanova USA, INC. | $133.54 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lilly USA, LLC | $123.08 | 2019-2024 | Emgality, Reyvow |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damien Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.